These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26457357)

  • 1. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
    Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
    Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors.
    Gong L; Bui MM; Zhang W; Sun X; Zhang M; Yi D
    Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors.
    Nohr E; Lee LH; Cates JM; Perizzolo M; Itani D
    Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.
    Righi A; Mancini I; Gambarotti M; Picci P; Gamberi G; Marraccini C; Dei Tos AP; Simi L; Pinzani P; Franchi A
    Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach.
    Kervarrec T; Collin C; Larousserie F; Bouvier C; Aubert S; Gomez-Brouchet A; Marie B; Miquelestorena-Standley E; Le Nail LR; Avril P; Christophe Pagès J; de Pinieux G
    Mod Pathol; 2017 Mar; 30(3):393-406. PubMed ID: 28059095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
    Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
    Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly recurrent H3F3A mutations with additional epigenetic regulator alterations in giant cell tumor of bone.
    Ogura K; Hosoda F; Nakamura H; Hama N; Totoki Y; Yoshida A; Ohashi S; Rokutan H; Takai E; Yachida S; Kawai A; Tanaka S; Shibata T
    Genes Chromosomes Cancer; 2017 Oct; 56(10):711-718. PubMed ID: 28545165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.
    Yamamoto H; Iwasaki T; Yamada Y; Matsumoto Y; Otsuka H; Yoshimoto M; Kohashi K; Taguchi K; Yokoyama R; Nakashima Y; Oda Y
    Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.
    Venneker S; Szuhai K; Hogendoorn PCW; Bovée JVMG
    Virchows Arch; 2020 Jan; 476(1):135-146. PubMed ID: 31728625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. H3F3A-mutated giant cell tumour of bone without giant cells-clinical presentation, radiology and histology of three cases.
    Leinauer B; Wolf E; Werner M; Baumhoer D; Breining T; Luebke AM; Maas R; Schultheiß M; von Baer A; Sufi-Siavach A; Moritz C; Geißler S; Mellert K; Möller P; Barth TFE; Jundt G
    Histopathology; 2021 Nov; 79(5):720-730. PubMed ID: 33991114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant.
    Lüke J; von Baer A; Schreiber J; Lübbehüsen C; Breining T; Mellert K; Marienfeld R; Schultheiss M; Möller P; Barth TFE
    Histopathology; 2017 Jul; 71(1):125-133. PubMed ID: 28211081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma.
    Amary MF; Berisha F; Mozela R; Gibbons R; Guttridge A; O'Donnell P; Baumhoer D; Tirabosco R; Flanagan AM
    Histopathology; 2016 Jul; 69(1):121-7. PubMed ID: 26844533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
    Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone.
    Giesche J; Mellert K; Geißler S; Arndt S; Seeling C; von Baer A; Schultheiss M; Marienfeld R; Möller P; Barth TF
    J Pathol; 2022 Aug; 257(5):687-696. PubMed ID: 35522566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone.
    Behjati S; Tarpey PS; Presneau N; Scheipl S; Pillay N; Van Loo P; Wedge DC; Cooke SL; Gundem G; Davies H; Nik-Zainal S; Martin S; McLaren S; Goodie V; Robinson B; Butler A; Teague JW; Halai D; Khatri B; Myklebost O; Baumhoer D; Jundt G; Hamoudi R; Tirabosco R; Amary MF; Futreal PA; Stratton MR; Campbell PJ; Flanagan AM
    Nat Genet; 2013 Dec; 45(12):1479-82. PubMed ID: 24162739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histones and their practical application in bone tumors: Do I always need them?
    Reith JD
    Hum Pathol; 2024 May; 147():92-100. PubMed ID: 38307341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3.3 K36M Mutation as a Clinical Diagnosis Method of Suspected Chondroblastoma Cases.
    Mu H; Jiang Y; Xue L; Hua Y; Lin J; Cai Z
    Orthop Surg; 2021 Apr; 13(2):616-622. PubMed ID: 33620145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characterization of malignant chondroblastoma: a neoplasm with locally aggressive behavior and metastatic potential that closely mimics chondroblastoma-like osteosarcoma.
    Papke DJ; Hung YP; Schaefer IM; Bredella MA; Charville GW; Reith JD; Fletcher CDM; Nielsen GP; Hornick JL
    Mod Pathol; 2020 Nov; 33(11):2295-2306. PubMed ID: 32601382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene of the month: H3F3A and H3F3B.
    Aldera AP; Govender D
    J Clin Pathol; 2022 Jan; 75(1):1-4. PubMed ID: 34782425
    [No Abstract]   [Full Text] [Related]  

  • 20. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.